tolvaptan has been researched along with Auricular Fibrillation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Gao, Y; He, X; Liu, W; Shi, L; Wang, W; Zhuang, X | 1 |
| Harada, S; Horie, H; Kishimoto, Y; Nakamura, Y; Nishimura, M; Onohara, T; Otsuki, Y | 1 |
| Li, G; Liu, R; Ma, Z; Wang, W; Yuan, M; Zhang, K; Zhang, Y | 1 |
| Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P | 1 |
4 other study(ies) available for tolvaptan and Auricular Fibrillation
| Article | Year |
|---|---|
Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection.
Topics: Antidiuretic Hormone Receptor Antagonists; Aortic Dissection; Atrial Fibrillation; Diuretics; Humans; Retrospective Studies; Sodium; Tolvaptan; Urea | 2023 |
Tolvaptan can limit postoperative paroxysmal atrial fibrillation occurrence after open-heart surgery.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Care; Postoperative Complications; Postoperative Period; Time Factors; Tolvaptan | 2020 |
Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Chronic Disease; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Atria; Heart Rate; Hypoxia; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 9; MicroRNAs; Rats, Sprague-Dawley; Signal Transduction; Tolvaptan | 2018 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload | 2008 |